Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $227.85 Average PT from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty research firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price […]

Related Keywords

Michaelw Bonney ,Sanfordc Bernstein ,Stifel Nicolaus ,First Trust Direct Indexing ,Securities Exchange Commission ,Alnylam Pharmaceuticals Inc ,Institutional Investors Weigh In On Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Stock ,Analyst Recommendations For Alnylam Pharmaceuticals ,Citigroup ,Vanguard Personalized Indexing Management ,Alnylam Pharmaceuticals ,Nasdaq ,Ep Wealth Advisors ,News Ratings For Alnylam Pharmaceuticals Daily ,Daiwa Securities Group Inc ,Get Free Report ,Director Michael ,Exchange Commission ,Financial Advisors ,Personalized Indexing Management ,Securities Group ,Get Free ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Ratings ,Consensus ,